MDxHealth SA (NASDAQ:MDXH) Shares Bought by AWM Investment Company Inc.

AWM Investment Company Inc. grew its stake in MDxHealth SA (NASDAQ:MDXH - Free Report) by 11.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,721,290 shares of the company's stock after purchasing an additional 471,290 shares during the period. AWM Investment Company Inc. owned approximately 9.98% of MDxHealth worth $11,189,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Oppenheimer & Co. Inc. lifted its holdings in MDxHealth by 100.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock worth $47,000 after buying an additional 10,000 shares during the period. Perkins Capital Management Inc. boosted its position in MDxHealth by 31.6% in the 4th quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock worth $2,331,000 after purchasing an additional 236,100 shares in the last quarter. Geode Capital Management LLC acquired a new stake in MDxHealth during the fourth quarter valued at $25,000. Samjo Management LLC raised its position in shares of MDxHealth by 130.9% in the fourth quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock worth $4,324,000 after acquiring an additional 1,034,312 shares during the period. Finally, Renaissance Technologies LLC boosted its position in MDxHealth by 715.2% during the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock worth $292,000 after purchasing an additional 108,000 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a research report on Saturday.

MDxHealth Trading Down 1.0%

Shares of NASDAQ MDXH traded down $0.02 during mid-day trading on Monday, reaching $2.04. 60,462 shares of the company's stock were exchanged, compared to its average volume of 86,415. The company's 50-day moving average is $1.67 and its 200-day moving average is $1.85. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The firm has a market capitalization of $96.47 million, a price-to-earnings ratio of -1.34 and a beta of 1.32. MDxHealth SA has a 52-week low of $1.35 and a 52-week high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.06). MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $24.29 million during the quarter, compared to analysts' expectations of $22.62 million. Analysts expect that MDxHealth SA will post -1.15 EPS for the current fiscal year.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.